Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection.
about
Dengue virus pathogenesis: an integrated viewDengue virus requires the CC-chemokine receptor CCR5 for replication and infection developmentEndothelial cells in dengue hemorrhagic feverMouse models to study dengue virus immunology and pathogenesisDengue viruses - an overviewA model of DENV-3 infection that recapitulates severe disease and highlights the importance of IFN-γ in host resistance to infectionIFN-γ production depends on IL-12 and IL-18 combined action and mediates host resistance to dengue virus infection in a nitric oxide-dependent mannerLethal antibody enhancement of dengue disease in mice is prevented by Fc modificationActivation of Nrf2 by the dengue virus causes an increase in CLEC5A, which enhances TNF-α production by mononuclear phagocytesMurine Model for Dengue Virus-Induced Lethal Disease with Increased Vascular PermeabilityRecent Advances in Deciphering Viral and Host Determinants of Dengue Virus Replication and PathogenesisTranscriptional Activation of Interferon-Stimulated Genes but Not of Cytokine Genes after Primary Infection of Rhesus Macaques with Dengue Virus Type 1Dengue Virus (DV) Replication in Monocyte-Derived Macrophages Is Not Affected by Tumor Necrosis Factor Alpha (TNF- ), and DV Infection Induces Altered Responsiveness to TNF- StimulationDifferential Gene Expression Changes in Children with Severe Dengue Virus InfectionsPhenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue feverTumor Necrosis Factor Alpha Protects against Lethal West Nile Virus Infection by Promoting Trafficking of Mononuclear Leukocytes into the Central Nervous SystemEssential role of platelet-activating factor receptor in the pathogenesis of Dengue virus infectionA genetic and pathologic study of a DENV2 clinical isolate capable of inducing encephalitis and hematological disturbances in immunocompetent miceFirst experimental in vivo model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodiesRole of the chemokine receptors CCR1, CCR2 and CCR4 in the pathogenesis of experimental dengue infection in mice.Subversion of early innate antiviral responses during antibody-dependent enhancement of Dengue virus infection induces severe disease in immunocompetent mice.Acute Systemic Infection with Dengue Virus Leads to Vascular Leakage and Death through Tumor Necrosis Factor-α and Tie2/Angiopoietin Signaling in Mice Lacking Type I and II Interferon ReceptorsSB203580 Modulates p38 MAPK Signaling and Dengue Virus-Induced Liver Injury by Reducing MAPKAPK2, HSP27, and ATF2 PhosphorylationMaternal Antibody-Mediated Disease Enhancement in Type I Interferon-Deficient Mice Leads to Lethal Disease Associated with Liver DamagePeptide Bbeta(15-42) preserves endothelial barrier function in shock.Differential induction of cytokines by human neonatal, adult, and elderly monocyte/macrophages infected with dengue virus.Dengue vaccines: recent developments, ongoing challenges and current candidates.Phenotypic characterization of patient dengue virus isolates in BALB/c mice differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome.A detrimental role for invariant natural killer T cells in the pathogenesis of experimental dengue virus infection.A preliminary randomized double blind placebo-controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal.Activation of MDL-1 (CLEC5A) on immature myeloid cells triggers lethal shock in miceActivation of TLR2 and TLR6 by Dengue NS1 Protein and Its Implications in the Immunopathogenesis of Dengue Virus Infection.Dengue hemorrhagic fever-associated immunomediators induced via maturation of dengue virus nonstructural 4B protein in monocytes modulate endothelial cell adhesion molecules and human microvascular endothelial cells permeability.Pathogenesis of malaria and clinically similar conditions.Peripheral Organs of Dengue Fatal Cases Present Strong Pro-Inflammatory Response with Participation of IFN-Gamma-, TNF-Alpha- and RANTES-Producing Cells.Characterization of lethal dengue virus type 4 (DENV-4) TVP-376 infection in mice lacking both IFN-α/β and IFN-γ receptors (AG129) and comparison with the DENV-2 AG129 mouse model.Contributions of mast cells and vasoactive products, leukotrienes and chymase, to dengue virus-induced vascular leakage.Isolation of dengue virus serotype 4 genotype II from a patient with high viral load and a mixed Th1/Th17 inflammatory cytokine profile in South Brazil.Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection.Animal models of dengue virus infection
P2860
Q24645380-3C052682-387C-4DF9-98CA-17FFD2AF260FQ26700116-D293A105-C0A8-49C7-9F7E-C0900DD814DDQ26825663-BEC63B74-D5E5-4D20-B185-977BCC8664A3Q27010151-4C7B0D2E-1A28-431E-B082-13AD11680877Q27026302-96C275E8-ECCC-4B13-9ABC-BEFBFA13CD21Q27305445-CD33B814-FEF6-480E-A12E-EA707DD93157Q27305770-C17199B2-CD76-42F3-B75F-BE7595684658Q27315772-FFFF6E9F-2A67-443E-B097-11622BECA1B2Q27468820-F2AD1A66-85B2-42A7-A5CF-8A2B038525B8Q27477548-B2ADF13B-9ACE-4CE1-B649-2EE20FD4DAECQ27477646-27A9BB83-6EAA-4DDD-B866-EBF8BFDE8751Q27480996-77A0DA56-801D-42CE-808E-289CA1360B80Q27481475-BB5077E2-B2DB-4DFB-ADD4-70B9A7E539E9Q27485627-D8F74E34-3FDF-41F1-8EFB-502F13139349Q27486912-182EAC40-2E95-4180-9FD9-3DB655BE94B8Q27486917-D16C59E9-830C-4F2C-98F2-539D93EACB7AQ27489378-F862B487-5A95-4683-8216-7E4BB4784A66Q28483765-9C1AE0D5-08CA-43E0-9A1F-379634AAF85DQ31156754-7C48AD24-2414-4DDD-B20C-D7400D3AB1CEQ33393510-2EBE22C9-2B2F-492C-A295-505D4EF3BA12Q33414560-2100007A-4805-4C90-BA2F-315C8BECD32EQ33429775-5CFFFF6D-8D9C-46F6-A29B-BA07E19CE95FQ33430173-B290E95A-064A-43BB-9BCC-1F8068F4944DQ33430984-1A5F6D36-9B19-49A6-839C-E97A5F72F049Q33436206-008E3759-A7F8-45FD-90A2-38BC7421B6DDQ33630197-74B36E4D-F7EE-44FF-8BB1-BB62CE6D094FQ34367194-439AEE6B-FB5A-47D0-B456-6E29CD47E012Q35206380-1055845D-719A-4C09-943A-4866920FDFC2Q35235639-290E0694-F7FB-4926-B11D-C72F64A29A27Q35464299-E42B342E-611D-4F7E-B6DD-75003D380BEFQ35484895-F4F0B6E7-8DE9-4FB1-9C61-970DE881F702Q35727211-444409AB-8773-4A2A-89D5-F687A4E4BB0DQ35739855-2ABAC831-93ED-4AA0-AABF-BD021E0EC02AQ35838590-405D7C60-0EB9-43A2-813F-59FFA3E16F99Q36231756-E5A5AC67-5EEA-44AC-873F-47A459AAE7D3Q36255068-0306C532-9767-4F2E-AFAA-085785013110Q36804428-74438213-01AF-460B-9E06-85BE1487F449Q36976236-4E8DE791-5073-460E-9186-547676A7E3F6Q37123259-4695562E-DEEF-49A2-806E-71FC4B39D42DQ37987131-5742509E-141A-4DD4-8EB2-8245F33A04A3
P2860
Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection.
@ast
Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection.
@en
type
label
Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection.
@ast
Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection.
@en
prefLabel
Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection.
@ast
Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection.
@en
P2093
P921
P1476
Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection.
@en
P2093
Alena Atrasheuskaya
George Ignatyev
Terry M Fredeking
P356
10.1111/J.1574-695X.2003.TB00646.X
P577
2003-01-01T00:00:00Z